The global IgA nephropathy treatment market was valued at USD 2.50 billion in 2023 and is projected to grow at a CAGR of 19.85% from 2024 to 2032, reaching approximately USD 12.78 billion by 2032. The market growth is driven by the rising prevalence of IgA nephropathy, increasing diagnosti